Hikal Limited Q2 FY26 Concall Decoded: – ₹80 cr revenue vanished, margins collapsed, but management promises a heroic H2 comeback
1. Opening Hook
Hikal’s Q2 FY26 concall felt like watching a medical drama where the patient is stable, bleeding, and confidently telling doctors, “Don’t worry, I’ll run a marathon next quarter.” Revenue showed up, EBITDA barely did, and profits quietly exited the building. The real villain? A US FDA warning letter and ₹80 crore of sales that technically existed—but emotionally didn’t.
Management insists nothing is broken, customers are loyal, orders are intact, and everything magically restarts in H2. Investors, meanwhile, are stuck choosing between trusting long-term CDMO nirvana and staring at a 2.6% EBITDA margin wondering what went wrong—again.
This wasn’t a disaster call, but it wasn’t comforting either. It was a classic “trust us” performance, heavy on future pipelines, light on present profitability.
Read on. The excuses are detailed, the optimism is bold, and the patience required is… considerable.
2. At a Glance
Revenue ₹319 cr – Respectable headline, minus ₹80 cr that slipped into October.
EBITDA ₹8 cr – Blink and you miss it.
EBITDA margin 2.6% – Pharma company briefly cosplaying as a trading firm.
H1 EBITDA ₹32 cr – Still struggling to lift its head.
Debt-equity at 0.55 – Balance sheet behaving better than P&L.
3. Management’s Key Commentary
“Demand visibility is improving quarter by quarter.” (Translation: Please ignore this quarter and focus emotionally on the next one.) 😏
“Sales were deferred due to customer risk assessments.” (Translation: The revenue existed, just not in September.)
“No customer has cancelled orders.” (Translation: They paused, panicked, then came back.)
“We expect a strong recovery in Q3 and Q4.” (Translation: This sentence has been copy-pasted from Q1.)
“CAPA implementation is well advanced.” (Translation: Consultants are expensive, but unavoidable.)
“CDMO pipeline quality has improved significantly.” (Translation: Revenues will come—eventually.)
